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ABSTRACT: Survival of patients with metastatic pheochromocytoma that
have exceeded 30 years without therapy to reduce tumors have been re-
ported. We reviewed the records of 38 patients with malignant pheochro-
mocytoma who had received 131I-metaiodiobenzylguanidine (131I-MIBG)
treatments between 1981 and 1996 to evaluate longevity. Survival from di-
agnosis to last follow-up exceeded 5 years in 21 of 38 (55%) and ≥10 years
in 50%. In 17 of 21, the interval from diagnosis to 131I-MIBG therapy
was greater than 5 years. Survival following 131I-MIBG was ≥5 years in
12 of 17 and ≥10 years in 7 of 17 patients despite continued evidence of
excessive circulating catecholamines. Objective responses to 131I-MIBG
therapy were seen in about 30% and were usually of a few years, duration,
but one individual exhibited marked reductions in volume and function of
tumors that have persisted for 21 years. No feature, including a remission
of >5 years following surgical excision, was found to predict prolonged
survival. In summary, many patients with malignant pheochromocytoma
will follow a course extending over many years. The role of 131I-MIBG
therapy in longevity is uncertain, but this radiopharmaceutical reduces
evidence of tumors in some patients. Criteria for selecting patients who
will benefit from treatment remain to be determined.
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INTRODUCTION
In the strategy of therapy for potentially lethal diseases, prolongation of
life is paramount. To appreciate beneficial effects, the probable courses of
the disorder without treatment must be taken into account. Survival of pa-
tients with malignant pheochromocytoma, even those with distant metastases,
has exceeded 10 years.1–10 Tumor doubling time is then likely to be more
than 2 years. These patterns prompted the review of patients with malignant
pheochromocytoma initially seen at the University Michigan from 1981 to
1995 for treatments with 131I-metaiodobenzylguanidine (MIBG). The periods
of time before and after the therapies were given special attention.
A number of patients who eventually developed malignant pheochromo-
cytoma appeared to have a benign, completely resected, tumor at the outset;
more than 5 years between diagnosis and recurrence has not been rare.5,6,11–13
These observations have led some to recommend that all patients treated for
pheochromocytoma should have reevaluations for extended periods of time
with the expectation of eventually uncovering malignancy.11–13 How this man-
ifestation affects survival has not been closely examined. Nine of our patients
treated with 131I-MIBG exhibited this phenomenon. For these individuals, the
intervals between initial operation and recrudescence are recorded, and these
periods are related to their subsequent survival.
MATERIALS AND METHODS
Thirty-eight patients were treated with one to six intravenous infusions of
131I-MIBG for malignant pheochromocytoma between 1981 and 1995 (treat-
ments completed in 1996). Nearly all received multiple infusions, often at in-
tervals of 3 to 4 months but some were extended through a period of 3 years, and
one patient received four courses of therapy over 4.5 years. Results have been
published for 28 patients treated with 131I-MIBG alone14 and 6 who received
the radiopharmaceutical followed by chemotherapy.15 Four additional patients
were given 131I-MIBG between those two studies. The available records were
reviewed, but for three patients too little information was available to assess
the intervals in question.
RESULTS
Of the 38 patients, 21 (55%) were known to have survived for >5 years
(7–45 years of age), and 50% were alive for ≥10 years following the diagnosis
of pheochromocytoma (TABLE 1). Of these 21 patients, the age at diagnosis
ranged from 10 to 69 years; only 3 of these patients were females. Information
on the remaining 17 patients was sparse: the age at diagnosis ranged from
14 to 66 years; seven were females; and at least three died within 5 years of
diagnosis.
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Manifestations of excessive catecholamines, symptoms, and hypertension
were present in each of the 21 subjects listed in TABLE 1. The pheochromocy-
toma in patient 11 arose as a component of MEN 2 A. Associated disorders
of polycythemia in patients 8 and 18 and a familial hypercoagulation state
in patient 12 suggested the possibilities of syndromes, but no genetic tests
for germline mutations that result in pheochromocytomas were done. In only
patient 11, who manifested MEN 2 A, was there a family history of pheochro-
mocytoma.
The time from diagnosis of pheochromocytoma to treatment with 131I-MIBG
ranged from 0.1 years to 20 years (TABLE 1). This interval exceeded 5 years in
all but 4 patients, and in 13 it was ≥10 years. None of the patients attained a
complete remission following treatments (as noted previously).14,15 In our prior
evaluations, about 30% of those treated with 131I-MIBG were shown to have
objective decreases in tumor volume and/or hormone metabolite secretions
from the tumors. Recent information recorded that patient 1 exhibited a marked
reduction in tumor volume and function that has persisted for 21 years after
radiopharmaceutical therapy.
From the longevity data available on 17 patients, the interval after 131I-MIBG
treatments was at least 5 years for 12 patients, >10 years for 7, and >20 years
for 3 (TABLE 1), each with evidence of persisting tumors. However, in the 12
patients surviving for at least 5 years, a relationship was not apparent between
the interval spanning diagnosis to 131I-MIBG therapy, ranging from 0.1 years to
20 years, and the subsequent survival of 5–21 years. Nor was the occurrence of
partial remissions, seen in patients 1, 2, 4, 9, and 12, associated with a distinct
pattern of post-therapy survival, 4–21 years (TABLE 1). Moreover, patients 6,
8, 16, 18, and 21 manifested no objective responses to treatment, but their
survivals were among the longest.
Ten patients manifested recurrences more than 5 years after the initial re-
section of a pheochromocytoma that was thought to be curative (TABLE 1,
footnotea). These individuals had been cared for by a variety of physicians in
multiple institutions, and it is unknown how frequently, and with what labo-
ratory tests, evaluations were carried out in the interlude. These individuals
appeared to live longer after initial diagnosis, but, from the incomplete follow-
up data, there was no real difference in survival subsequent to 131I-MIBG
treatments.
DISCUSSION
Ascertainment bias will afflict studies of any rare tumor. Some malignant
pheochromocytomas may cause inanition and death within a few months of
diagnosis, and patients with such tumors would have been excluded from
our study. Nevertheless, it appears that, in a number of individuals, malignant
pheochromocytoma may progress very slowly, even over decades. This concept
is supported in 11 reports of ≥10-year survival in the presence of metastatic
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disease: one patient dying at 20 years1; three reaching ≥20 years2; one living
for 25 years3; one alive at 21 years4; two living longer than 20 years5; two of
14 patients, longest 22 years6; one surviving 26 years7; one alive for more than
30 years8; one alive at 16 years;9 one dead after 11 years.10
In our 38 patients, survivals from time of diagnosis were greater than
5 years in at least 55% and greater than 10 years in 50%. The role of 131I-MIBG
treatment in longevity remains uncertain. An interval of ≥10 years from di-
agnosis to treatment was present in 13 patients and already gave evidence of
slow progression of disease. Some patients had objective improvements fol-
lowing 131I-MIBG treatments, but the benefits were incomplete, and, except
in two patients, sustained for only a few years. A pattern of infrequent, partial,
and temporary responses to 131I-MIBG is similar to that reported by others,
as noted in reviews of the literature.16,17 In recent reports, rates of objective
improvements have been similar in six10 and 33 patients.18 However, 3 of 12 in-
dividuals treated with high-dose 131I-MIBG exhibited complete remissions; 2
of the remitted pheochromocytomas were nonsecretory, but the disappearance
of scintigraphic and CT evidence of disease has endured for 8.5 years in one.19
In addition, two patients had marked partial responses to multiple 131I-MIBG
therapies, and, in one, diminutions of tumor have persisted for 16 years.10 And
one of our patients enjoyed substantial reductions in tumor volume and hor-
monal markers that have been sustained for 21 years. These latest observations
give hope of long-term effects from 131I-MIBG therapy, but enhanced survival
will require study of numerous patients over decades.
When considering therapy for a patient with malignant pheochromocytoma,
is there any way to predict the course of disease? Observations for a period of
many months may be insufficient to predict accurately the long-term course
a patient will take; for example, two of our patients (patients 18 and 21) ap-
peared to have developed extensive metastases during the few years following
diagnosis and then manifested stable patterns of disease for a prolonged period
before 131I-MIBG treatment. It is possible that growth-inhibiting substances,
released by paracrine or autocrine mechanisms from the tumors, and/or acti-
vation of autoimmune forces brought about this pattern of malignant growth.
Identification of such inhibiting factors could not only predict the course of
disease but also lay a basis for new therapeutics.
Research into tumor-suppressor genes,20 angiogenetic forces,21 and pro-
teomics22 may lead to accurate predictions of which tumors will progress
rapidly. Other types of analyses have shown that plasma methoxytyramine
and dopamine levels have been associated with multiple deposits of tumor;23
these, and possibly other, catecholamine-related products may be portents of
aggressive malignancy.
Without predictors of the course of malignant pheochromocytoma, it will
be difficult to withhold treatment in a symptomatic patient while awaiting a
pattern of progression to appear. Objective responses observed in indices of
tumor function and volume over a year or two following treatments may be the
best guides of success.
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Why some malignant pheochromocytomas recur years after apparently com-
plete resection is unknown. The reappearance of tumor more than 5 years after
surgical excision was seen in 10 of our patients. This early delay in tumor
progression was not associated with a greater overall longevity than that seen
in the patients whose residual malignancy was observed sooner. In the litera-
ture, 3–8% of patients who were originally thought to harbor benign disease
have developed recurrences after 5 years: one patient (cohort not described)5;
two of 14 patients6; three of 9811; 14 of 17612; and five of 121.13 In at least
one series, urinary catecholamines and metabolites were found to be normal
after the operation.11 For patients with apparently benign pheochromocytoma,
prediction of events will be difficult, but proteomics offers some hope,22 and,
if measured at regular intervals, the plasma-free metanephrines, which offer
high sensitivities,24,25 may provide an early clue.
In summary, patients with malignant pheochromocytoma may exhibit a slow
progression of disease extending over decades. Years of observation are nec-
essary to project the ultimate course. However, without early prognosticators,
therapy that is found to help at least some patients cannot be withheld. Still,
success must include accurate measurements of survival. For the few patients
who will have delayed recurrence after initial excision, methods must be de-
vised to detect these resurgent tumors at the earliest time to give the best
opportunity for cure through reoperation.
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